Figure 2: RRMS patients have reduced serum cholesterol efflux capacity via ABCG1 and reduced monocyte ABCG1 mRNA expression compared to healthy controls. | Scientific Reports

Figure 2: RRMS patients have reduced serum cholesterol efflux capacity via ABCG1 and reduced monocyte ABCG1 mRNA expression compared to healthy controls.

From: Relapsing-remitting multiple sclerosis patients display an altered lipoprotein profile with dysfunctional HDL

Figure 2

(a) LCAT mass (μg/ml) was measured in freshly thawed plasma samples of HC (n = 21) and RRMS (n = 22) patients using ELISA. (b) Schematic representation of sHDL measured by NMR, based on 2D gelelectrophoresis, and ultracentrifugal separation. (c) Capacity of serum from controls (n = 50), RRMS (n = 26), and progressive MS (n = 17) patients to accept cholesterol via the ABCA1 (left) or ABCG1 (right) transporters from 3H-cholesterol loaded BHK cells transfected with human ABCA1 or ABCG1 respectively. (d) Basal ABCA1 (left) and ABCG1 (right) mRNA expression in monocytes of HC (n = 43), RRMS (n = 33), and progressive MS (n = 7) patients measured using quantitative PCR (qPCR). Results are expressed as fold change of healthy controls. (e), Pearson correlation coefficient for percentage serum cholesterol efflux capacity via the ABCG1 transporter versus sHDL (μmol/L) for RRMS patients with a low BMI (n = 10). *P < 0.05, ****P < 0.0001.

Back to article page